Clinical Trials

Working on tomorrow's treatments today

Oraxol is a combination of paclitaxel with a novel p-glycoprotein (P-gp) inhibitor, HM30181 Methanesulfonate monohydrate. Oraxol is being evaluated in a study entitled:  “A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects with Advanced Malignancies.”

This study is being done at the following cancer research centers:

  • Roswell Park Cancer Institute (Buffalo, NY)
  • University of Colorado Cancer Center (Aurora, CO)
  • Johns Hopkins University (Baltimore, MD)

To inquire about participation in this study, contact the study coordinator at the site. Contact information can be found at clinicaltrials.gov.

________________________________________________________________________________________

KX01 is an oral agent that has a dual mechanism of action resulting in broad activity but selectively targets proteins that are involved in the growth and development of cancer. KX01 is being evaluated in a “Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy.”

This study is being done at the following cancer research centers:

  • Roswell Park Cancer Institute (Buffalo, NY)
  • Thomas Jefferson University (Philadelphia, PA)
  • Cornell University- Weill Medical College (New York, NY)

To inquire about participation in this study, contact the study coordinator at the site. Contact information can be found at clinicaltrials.gov.